Goljan - Genetic and Developmental Disorders Chapter Flashcards
Sickle cell disease
Sickle hemoglobin; autosomal recessive
Cystic fibrosis
Cystic fibrosis transmembrane regulator (CFTR); autosomal recessive
Familial hypercholesterolemia
Low-density lipoprotein (LDL) receptor; autosomal dominant
Neurofibromatosis
Neurofibromin; autosomal dominant
Hemophilia A
Factor VIII; X-linked recessive
Deficient enzyme in alkaptonuria
Homogentisate oxidase
Clinical findings in alkaptonuria
- Black urine (undergoes oxidation when exposed to light)
- Black pigmentation of nose, ears, cheeks
- Black cartilage in joints and intervertebral discs, producing degenerative arthritis
Biochemical findings in alkaptonuria
- Increased homogentisate (black pigment), which binds to collagen in connective tissue, tendons, cartilage
- Decreased maleylacetoacetate
Deficient enzyme in galactosemia
Galactose-1-phosphate uridyltransferase (GALT)
Biochemical findings in galactosemia
- Increased galactose-1-phosphate –> toxic to liver and CNS
- Increased galactose in urine
- Increased galactitol –> sugar alcohol that produces osmotic damage in lens
- Decreased glucose-1-phosphate
- Decreased glucose-6-phosphate
- Decreased blood glucose in fasting state
Clinical findings in galactosemia
- Mental retardation
- Cirrhosis
- Fasting hypoglycemia (due to decrease in gluconeogenic substrates distal to block)
- Cataracts (due to osmotic damage)
Treatment for galactosemia
Avoid dairy products (galactose derives from lactose)
Deficient enzyme in hereditary fructose intolerance
Aldolase B
Biochemical findings in hereditary fructose intolerance
- Increase in fructose-1-phosphate –> toxic substrate
- Decreased glyceraldehyde-3-phosphate
- Decreased dihydroxyacetone phosphate (DHAP)
- Decreased glucose in the fasting state
Clinical findings in hereditary fructose intolerance
- Cirrhosis
- Hypoglycemia (due to decrease in gluconeogenic substrates)
- Hypophosphatemia (used up in phosphorylating fructose)
Treatment for hereditary fructose intolerance
Avoid fructose (e.g., in honey) and sucrose (glucose + fructose)
Deficient enzyme in homocystinuria
Cystathionine synthase
Biochemical findings in homocystinuria
- Increased homocysteine and methionine levels
2. Decreased cystathionine
Clinical findings in homocystinuria
- Mental retardation
- Vessel thrombosis (due to homocysteine accumulation)
- Lens dislocation and arachnodactyly (similar to Marfan syndrome)
Deficient enzyme in maple syrup urine disease
Branched chain alpha-ketoacid dehydrogenase
Biochemical findings in maple syrup urine disease
- Increased isoleucine –> decreased acetyl CoA + decreased succinyl CoA
- Increased leucine –> decreased acetyl CoA + acetoacetate
- Increased valine –> decreased succinyl CoA
Clinical findings in maple syrup urine disease
- Mental retardation
- Seizures
- Feeding problems
- Sweet-smelling urine
Deficient enzyme in phenylketonuria
Phenylalanine hydroxylase
Biochemical findings in phenylketonuria
- Increased levels of phenylalanine and neurotoxic byproducts
- Decreased levels of tyrosine
Clinical findings in phenylketonuria
- Mental retardation
- Microcephaly
- Mousy odor (due to conversion of phenylalanine into phenylacids)
- Decreased skin pigmentation (melanin derives from tyrosine, the levels of which are reduced)
Treatment for phenylketonuria
- Restrict phenylalanine; avoid sweeteners containing phenylalanine (e.g., NutraSweet)
- Add tyrosine to diet
Pregnant women with PKU must be on a…or their newborns will be…at birth.
Phenylalanine-free diet; mentally retarded
Hereditary angioedema
C1 esterase inhibitor deficiency; autosomal dominant
Deficient enzyme in “malignant” phenylketonuria
Dihydropterin reductase
Accumulated substrates in “malignant” phenylketonuria
Phenylalanine and neurotoxic byproducts
Treatment for “malignant” phenylketonuria
- Restrict phenylalanine in diet
- Administer L-dopa and 5-hydroxytryptophan to replace neurotransmitters
- Administer BH4 (i.e., tetrahydrobiopterin)
Patients with “malignant” phenylketonuria are unable to metabolize…or…, resulting in decreased synthesis of…and…, respectively.
Tryptophan; tyrosine; serotonin; dopamine
Note: Metabolism of both tryptophan and tyrosine requires BH4.
Deficient enzyme in McArdle disease
Muscle glycogen phosphorylase
Biochemical findings in McArdle disease
- Increased glycogen
2. Decreased glucose
Clinical findings in McArdle disease
- Glycogenosis with muscle fatigue
- Propensity for rhabdomyolysis with myoglobinuria
- No lactic acid increase with exercise due to lack of glucose in muscle and a corresponding lack of anaerobic glycolysis
Deficient enzyme in Pompe disease
Alpha-1,4-glucosidase (lysosomal enzyme)
Clinical findings in Pompe disease
- Glycogenosis
2. Cardiomegaly with early death from heart failure (or, to be more specific, restrictive cardiomyopathy)
Accumulated substrate in patients with Pompe disease
Glycogen
Deficient enzyme in von Gierke disease
Glucose-6-phosphatase (gluconeogenic enzyme)
Biochemical findings in patients with von Gierke disease
- Increased glucose-6-phosphate
2. Decreased glucose
Clinical findings in von Gierke disease
- Glycogenosis
- Enlarged liver and kidneys (both contain gluconeogenic enzymes)
- Fasting hypoglycemia (no response to glucagon or other gluconeogenesis stimulators)
Deficient enzyme in Gaucher disease (type I)
Glucocerebrosidase
Most common lysosomal storage disease
Gaucher disease
Clinical findings in Gaucher disease type I
- Hepatosplenomegaly
- Fibrillar-appearing macrophages in liver, spleen, and bone marrow
- Pancytopenia from marrow involvement
- Hypersplenism from enlarged spleen
Note: There is no CNS involvement.
Treatment for Gaucher disease
Replacement therapy with recombinant enzyme is effective
Deficient enzyme in Hurler syndrome
Alpha-1-iduronidase
Biochemical findings in Hurler syndrome
Dermatan and heparin sulfate (mucopolysaccharides or glycosaminoglycans) accumulate in mononuclear phagocytic cells, lymphocytes, endothelial cells, intimal smooth muscle cells, and fibroblasts.
Describe the typical clinical course of Hurler syndrome.
Normal at birth but develop severe mental retardation and hepatosplenomegaly by 6-24 months.
Clinical features of Hurler syndrome
- Coarse facial features
- Short neck
- Corneal clouding
- Coronary artery disease
- Vacuoles in circulating lymphocytes
A milder form of Hurler syndrome is…, which is characterized by an…inheritance pattern.
Hunter syndrome; X-linked recessive
Deficient disease in Niemann-Pick disease
Sphingomyelinase
Accumulated substrate in Niemann-Pick disease
Sphingomyelin
…are present in 30-50% of Niemann-Pick cases.
Cherry red macula
Signs and symptoms of Niemann-Pick disease begin…
At birth.
Niemann-Pick disease type A is very severe and involves the…
CNS, causing psychomotor dysfunction and shortened lifespan.
Niemann-Pick disease type B does not involve the CNS and pts…
Survive into adulthood.
Laboratory findings in cases of Niemann-Pick disease
Phagocytic cells affected in liver (hepatomegaly), spleen (massive splenomegaly), lymph nodes, and bone marrow. Phagocytes have a foamy appearance; zebra bodies are seen on EM.
Deficient enzyme in Tay-Sachs disease
Hexosaminidase A
Accumulated substrate in Tay-Sachs disease
GM2 ganglioside
Describe the typical clinical course of Tay-Sachs disease.
Normal at birth but manifest signs and symptoms by 6 months of age.
Clinical findings in Tay-Sachs disease
- Muscle weakness
- Mental deterioration
- Whorled configurations in neurons
- Cherry-red macula (pale ganglion cells with excess gangliosides accentuate the normal red color of the macular choroid)